From the President:
The 10 x ’20 Initiative—Ten New Antibiotics by 2020 |
In recognition of the imbalance between the dwindling antibacterial drug pipeline and the significant clinical need for new antibiotics to treat antibacterial-resistant infections, IDSA has launched a new advocacy campaign called the
10 x '20 initiative—an effort to mobilize key leaders and resources around a specific goal—to create an antibacterial research and development enterprise powerful enough to produce 10 new antibiotics by the year 2020.
|
| IDSA Journal Club |
|
This month: Studies investigating maraviroc in the initial treatment of HIV, the low recurrence of hepatotoxicity when tuberculosis (TB) treatment is reinitiated using any of three different strategies, the effectiveness of the 7-valent pneumococcal vaccine in preventing invasive disease in adults with HIV, and the timing of HIV treatment in TB/HIV coinfection.
|
|
|
